Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Should patients with systemic sclerosis-related pulmonary arterial hypertension be anticoagulated?|
|Citation:||Internal Medicine Journal, 2013; 43(5):599-603|
|Publisher:||Blackwell Publishing Asia|
|M. Nikpour, W. Stevens, S. M. Proudman, R. Buchbinder, D. Prior, J. Zochling, T. Williams, E. Gabbay and H. Nandurkar|
|Abstract:||Pulmonary arterial hypertension (PAH) is a major cause of mortality in scleroderma and despite ‘advanced’ therapies confers a median survival of less than 5 years. Anticoagulation in systemic sclerosis-related PAH (SSc-PAH) is currently one of the most contentious issues in the management of patients with connective tissue disease. While some studies have shown a survival benefit with warfarin therapy in this disease, others have not. Accordingly, a state of clinical equipoise exists in relation to anticoagulation in SSc-PAH. With an over fivefold reduction in mortality demonstrated in some observational studies, the issue of anticoagulation in SSc-PAH demands resolution through a well-designed randomised controlled trial.|
|Keywords:||scleroderma; systemic sclerosis; pulmonary arterial hypertension; anticoagulation; randomised controlled trial|
|Rights:||© 2013 The Authors|
|Appears in Collections:||Medicine publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.